Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
filingDate |
1994-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5588fe26fd49b3d583ebd0aa56d97ad |
publicationDate |
1995-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0646582-A1 |
titleOfInvention |
Useful hemi-hydrate form of a cerebral function enhancing agent |
abstract |
The hemi-hydrate form of the cerebral function enhancing agent 1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]-methyl-2-pyrrolidinone, or BMY-21502 as it is more commonly designated, is an improved form of drug substance having equivalent biopharmaceutical properties compared to the known anhydrous form but providing cost, safety and ecological advantages in manufacture over the known anhydrous form. |
priorityDate |
1993-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |